PetrichorCapital Partners
PetrichorCapital Partners
Provides structured growth capital to facilitate the adoption of healthcare innovations
Petrichor Capital Partners makes structured investments across the global healthcare sector, with a focus on biopharmaceuticals, medical technology, diagnostics/tools, and tech-enabled services.
We provide growth investment solutions for late and commercial-stage companies.
We work with both public and private companies to support their long-term growth efforts and have deep experience with acquisitions, research & development activities, and commercial launches or expansions, among other situations.
Our investments enable leading healthcare innovators to reach the next stage of their evolution. Petrichor acts as a strategic advisor, partnering with management, Boards, and other investors to help ensure the success of our companies.
Petrichor Capital Partners in practice
Flexible Structures
Debt, equity and other structures tailored to a company’s needs.
High Growth Companies
Focused on late-stage or commercial public or private biopharma, medtech, and diagnostics companies, among others, providing capital for growth, M&A, and/or product development or launch, and beyond.
Enabling Long-Term Growth
Petrichor serves as value-added partner to execute long-term strategic vision.
Meet the team
The team has led over 125 investments, representing more than $6 billion of invested capital, and has sat on over 55 boards.
Meet the team
Portfolio
Discover the incredible companies that make up the Petrichor Capital Partners fund.
View portfolio
News
Read all newsITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
January 2025
Read more on 
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
January 2025
Read more on
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
January 2025
Read more on
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
January 2025
Read more on
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
January 2025
Read more on
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
January 2025
Read more on